SLN Divesiran: 88% Response in Phase 2 PV Trial

Silence Therapeutics (SLN) reported Monday that its siRNA drug divesiran crushed the primary endpoint in the Phase 2 SANRECO trial of phlebotomy-dependent polycythemia vera. The stock jumped 42% intraday to $16.95, adding roughly $235 million in market value.

The numbers: 88% of divesiran-treated patients achieved phlebotomy-free hematocrit control versus 19% on placebo, a 69-point placebo-adjusted gap (p<0.0001). Both dosing arms cleared independently: 93.8% at every-six-week dosing and 81.3% at every-twelve-week dosing. Divesiran also cut phlebotomies to 0.2 per patient versus 2.1 for placebo (p<0.0001). No new safety signals emerged in the 48-patient trial.

How divesiran works. The drug is a short interfering RNA that silences TMPRSS6, a gene in the liver that suppresses the iron-regulating hormone hepcidin. Removing that suppression raises hepcidin levels, which restricts iron delivery to the bone marrow and slows the red blood cell overproduction that drives PV. The mechanism targets the disease upstream of current treatments. The dosing advantage, one subcutaneous shot every twelve weeks, is a genuine differentiator for a chronic condition where patients already endure regular phlebotomies. PV is a rare blood cancer where elevated hematocrit above 45% is associated with a four-times higher risk of death from cardiovascular and thrombotic events, and divesiran holds FDA Fast Track and Orphan Drug designations.

The rusfertide overhang. Takeda and Protagonist’s rusfertide, a hepcidin mimetic peptide, was approved by the FDA on August 28, 2026 as MIMRYLO for erythrocytosis in polycythemia vera — the first FDA-approved hepcidin-targeted PV drug (see our MIMRYLO coverage). In the Phase 3 VERIFY trial, rusfertide achieved a 76.9% response rate. Divesiran’s 88% looks stronger on paper, but cross-trial comparisons carry the usual caveats: different patient populations, different endpoints, and only 48 patients in SANRECO. The dosing gap is clearer. Rusfertide requires weekly injections. Quarterly dosing, if confirmed in Phase 3, matters for real-world adherence.

What to watch. Silence plans to start Phase 3 in the first half of 2027, putting any approval no earlier than 2029. Between now and then, the company needs to fund a registrational program. With roughly $70 million in cash at last report, a financing raise is coming, and the post-data stock rally gives management an opportune window. Rusfertide will have a two-to-three-year commercial head start by the time divesiran could reach market. The Phase 3 will need to prove that infrequent dosing, four shots a year instead of fifty-two, closes that lead.

For investors learning to parse these readouts, the guide to clinical trial press releases covers what endpoints matter and why placebo-adjusted rates matter more than raw percentages.

Source: Silence Therapeutics press release, August 10, 2026 · SANRECO Phase 2 on ClinicalTrials.gov (NCT05499013)

What It Means for the Trade

A 42% intraday pop on a 48-patient Phase 2 is the market pricing a best-in-class story before any registrational data exists. Be clear about what SANRECO actually proved: divesiran beat placebo decisively in a small trial of phlebotomy-dependent PV. That is a strong Phase 2, not an approvable dataset. Phase 3 does not start until the first half of 2027, and approval is a 2029 event at the earliest. This rally is not a reason to buy the stock for the approval thesis — it is a reason to watch what management does with the window.

The first thing they will use it for is the raise. Roughly $70 million in cash does not fund a registrational polycythemia vera program. A post-data financing is close to inevitable, and the whole point of a 42% move is to make that raise less punishing. Dilution after a data spike is the standard small-cap biotech playbook; anyone buying the pop should be sizing for at least one dilution event before Phase 3 reads out.

Franchise and Competitive Context

The commercial question is not whether 88% beats 76.9%. That is a cross-trial comparison between 48 SANRECO patients and the larger Phase 3 VERIFY population, with different entry criteria and endpoints, and it proves nothing. The real question is whether four subcutaneous injections a year can take share from a weekly injectable in a market Takeda and Protagonist are building right now. Chronic rare-disease adherence data consistently favors less frequent dosing, and PV patients are already needle-fatigued from regular phlebotomies. If Phase 3 confirms the every-twelve-week arm — 81.3% response, still more than four times the placebo rate — the convenience gap becomes a genuine commercial weapon. The 93.8% every-six-week arm adds titration flexibility that a fixed weekly peptide cannot match.

Risks and What Could Go Wrong

1. Phase 3 fails to replicate. Small-n response rates routinely compress at scale. An 88% that drifts toward the low 70s in a registrational trial would still beat placebo but would kill the best-in-class premium. This is the base-case risk, not a tail risk.
2. Rusfertide entrenchment. By 2029, MIMRYLO will own the treating-center relationships, the formulary positions, and two to three years of real-world safety data. Best-in-class data does not automatically beat first-to-market.
3. Cash and calendar. Every financing round and every slipped quarter pushes approval further out. Treat this as a multi-year hold with a binary at the end, and position size accordingly.